Zeus Capital Research Director Robin Savage caught up with DirectorsTalk for an exclusive interview to discuss City of London Investment Group PLC (LON:CLIG) Q1: Now Robin, this morning City..
Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort that completed its Phase III..
Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss Evgen Pharma PLC (LON:EVG) Q1: Now we’re talking Evgen Pharma PLC..
Hardman and Co Research Analyst Head of Research Tony Williams caught up with DirectorsTalk for an exclusive interview to discuss the housebuilding sector for 2016/2017: what companies did and didn’t..
Zeus Capital Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview to discuss Elegant Hotels Group PLC (LON:EHG) Q1: Mike, Elegant Hotels Group PLC, can..
Headlam Group plc (LON:HEAD) saw strong trading in the last eight weeks of the year lead to further upgrades to forecasts, this follows the upgrades put through at the time..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today provides an update on trading for the six months ended 31 December 2016 ahead of..
Sirius Minerals Plc (LON:SXX) provides today an update on the future reporting of updates for its North Yorkshire polyhalite project following the successful completion of its Stage 1 Financing in..
UK Oil & Gas Investments PLC (LON:UKOG) announced today that UKOG Solent Limited, a 100%-owned subsidiary, has been advised that the Oil and Gas Authority has granted a one-year extension..
FairFX Group Plc (LON:FFX), the low cost multicurrency payments service, has today announced that it has agreed to acquire the entire issued ordinary share capital of Q Money Limited with..
Arria NLG plc (LON:NLG), a leader in Artificial Intelligence and Natural Language Generation, has today provided the following updates ahead of the cancellation of the Company’s ordinary shares (“Ordinary Shares”)..
